Invasive lobular carcinoma (ILC) is the second most common breast cancer subtype and
accounts for 8–14% of all cases. Although the majority of human ILCs are characterized by the …

53BP1 is a chromatin-binding protein that regulates the repair of DNA double-strand breaks
by suppressing the nucleolytic resection of DNA termini 1 , 2 . This function of 53BP1 …

BRCA1-mutated breast cancer is primarily driven by DNA copy-number alterations (CNAs)
containing large numbers of candidate driver genes. Validation of these candidates requires …

The limited efficacy of immune checkpoint inhibitor treatment in triple-negative breast cancer
(TNBC) patients is attributed to sparse or unresponsive tumor-infiltrating lymphocytes, but …

AXIN2 and LGR5 mark intestinal stem cells (ISCs) that require WNT/β-Catenin signaling for
constant homeostatic proliferation. In contrast, AXIN2/LGR5+ pericentral hepatocytes show …

Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast
growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer 1 . However, …

Poly(ADP-ribose) polymerase inhibition (PARPi) is a promising new therapeutic approach
for the treatment of cancers that show homologous recombination deficiency (HRD). Despite …

Large-scale sequencing studies are rapidly identifying putative oncogenic mutations in human
tumors. However, discrimination between passenger and driver events in tumorigenesis …

Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for
the treatment of homologous recombination (HR)-deficient cancers. Despite the success of …

Genetically engineered mouse models (GEMMs) of cancer have proven to be of great value
for basic and translational research. Although CRISPR‐based gene disruption offers a fast‐…